Search Results
Targeting aberrant non-canonical NF-κB pathway activation in B-cell lymphomas
The impact of biological heterogeneity on treatment outcomes is evidenced by a large proportion of lymphoma patients who experience relapsed/refractory disease. To address this knowledge gap, we sequenced primary lymphoma samples and found recurrent mutations in the non-canonical NF-kB pathway (NC NF-kB) and uncovered the NIK kinase as a targetable candidate. Our next steps focus on using advanced genetic modelling approaches to provide preclinical rationale for targeting NC NF-kB in lymphomas.T cell Memory in Cure of Diffuse Large B Cell Lymphoma: An Investigation of the Immune Interactome
While many patients with diffuse large B cell lymphoma (DLBCL) are cured with initial treatment, some patients relapse even after multiple therapies, and their outcomes are poor; we believe that the quality of the patient’s T cell memory plays a critical role in determining how they respond to treatment. To investigate, we will analyze the response pattern of circulating immune cells in cured and relapsed DLBCL patients, as well as the immune signals generated by the tumors, and create CAR T cells from the T cells with anti-tumor properties found in cured patients.Acalabrutinib
Acalabrutinib is a kinase inhibitor indicated for the treatment of adult patients with
- Mantle cell lymphoma (MCL) who have received at least one prior therapy
This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
- Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Polatuzumab vedotin-piiq
Polatuzumab vedotin-piiq is FDA approved
#ASH18: Update on Immunotherapy
Immunotherapy – harnessing the body’s immune system to fight disease – is rapidly becoming a mainstay of cancer treatment. The increasing interest in this field was clear at yesterday’s standing-room only symposium hosted by The Leukemia & Lymphoma Society in advance of the 60th ASH (American Society of Hematology) Meeting which officially kicks off today here in San Diego. Over the next few days more than 30,000 researchers and others connected to the blood cancers and other blood malignancies will gather to hear the latest data from clinical trials.
Helping Blood Cancer Patients and Caregivers Navigate the Financial Impact of COVID-19
The coronavirus (COVID-19) pandemic has been a challenging time for us all. It is especially so for cancer patients and survivors, who are at greater risk of getting sicker if they become infected with the virus because they might be immunocompromised.
Investigating the Impact of Insurance Coverage on Access to Care and Outcomes among Lymphoma Patients
In this proposal we will investigate the association between insurance coverage and access to care, survival, and financial hardship among patients across Non-Hodgkin lymphoma (NHL) subtypes and to what extent insurance coverage explains and modifies racial disparity in access to care and outcomes. To this end, we will use the Optum Clinformatics DataMart database, the Texas Cancer Registry, the Harris Health System Cancer Database and Data from the Lymphoma Epidemiology of Outcomes (LEO) Cohort Study.Ibrutinib
Ibrutinib has been FDA-approved to treat:
- Patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
- Patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (SLL) with 17p deletion.
- Patients with Waldenström macroglobulinemia (WM).
- Adult and pediatric patients age 1 year and older with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy.
Pembrolizumab
Pembrolizumab is FDA approved for the treatment of
Pirtobrutinib
Pirtobrutinib is indicated for the treatment of
Exploring the roles of EZH2 mutation for the development of double hit lymphoma and acquisition of chemotherapy resistance
We aim to clarify the role of EZH2 mutations in the development of double hit lymphoma (DHL) and acquisition of chemo-resistance. We confirmed that Ezh2 mutation is essential to develop aggressive murine GCB lymphoma and deplete T cells from tumor in combination with BCL2 and MYC. The mice showed resistance to chemotherapy and the combination with EZH2 inhibitors improve the outcome in vivo. Our goal is to show the synergy and propose a new mechanism-based therapeutic approach for DHL.Obinutuzumab
Obinutuzumab is FDA-approved
Refining Molecular Risk Prediction & Individualized Lymphoma Therapy Using Circulating Tumor DNA
My group studies variation in clinical outcomes of patients with aggressive lymphomas and tries to capture the underlying basis for this variation. We then integrate insights from our studies into molecular prediction tools that inform the probable outcomes of individual patients when treated with therapeutic regimens that are currently available. We hope to build precise risk models that have high predictive value for clinical outcomes of patients with lymphoma.MLB All-Star Player Designs Caps to Benefit LLS
The Leukemia & Lymphoma Society (LLS) hit a homerun when the Washington Nationals outfielder, Bryce Harper announced LLS will be a beneficiary of his limited edition, custom-designed baseball caps. Known for extraordinary talents in the outfield, Bryce’s talent as a hat designer is now getting recognition: He helped design the New Era caps which went on sale Wednesday, August 24.
Improving CAR-T cell therapy outcomes for patients with for aggressive lymphoma and multiple myeloma
Despite the promise of CAR-T cell immunotherapy for patients with lymphoma and multiple myeloma, a significant proportion of patients fail to respond or relapse following treatment. This project will focus on the clinical translation of a new treatment designed to improve durable response rates by combining CAR-T cell therapy with a new class of anticancer drugs called SMAC-mimetics. The results will provide the evidence base to drive a first-in-human clinical trial of this combination strategy.Cyclophosphamide
Cyclophosphamide is FDA approved to treat several types of cancer, including people who have Hodgkin lymphoma, non-Hodgkin lymphoma, acute and chronic lymphocytic leukemia, acute and chronic myeloid leukemia, myeloma, and mycosis fungoides. Cyclophosphamide is usually used in combination with other drugs.
Cyclophosphamide may cause a temporary loss of hair in some people. After treatment has ended, normal hair growth should return, although the new hair may be a slightly different color or texture.
Dacarbazine
Dacarbazine is used to treat people who have Hodgkin lymphoma as a second-line therapy when used in combination with other agents and is also used as initial therapy for some patients with Hodgkin lymphoma. It may cause a temporary loss of hair in some people. After treatment with dacarbazine has ended, normal hair growth should return.
XPO-1 as a novel therapeutic target in GATA-3 expressing mature T-cell lymphomas
GATA-3 identifies high-risk subtypes of mature T-cell lymphomas (MTCL), as its target genes, which we have systematically identified, have significant cell-autonomous and non-cell-autonomous (by regulating constituents of the tumor microenvironment) roles in these MTCL. As our preliminary data suggests that XPO-1 inhibition is a novel, and largely unexplored, therapeutic strategy in these MTCL, we will examine its cell-autonomous (Aim #1) and non-cell-autonomous (Aim #2) role in GATA-3+ MTCL.Hawks Legend Surprises Young Fan & Survivor
At 23 years old, Alex Hawkins just started a new job, had a great boyfriend and was an active runner. She spent her free time watching Atlanta Hawks games – she was a fan since she could talk – and enjoying time with her family, chasing around her two nephews while in the midst of helping her sister prepare for a new baby.
After finding an abnormal lump on her neck in 2014, she was diagnosed with B-Cell Non-Hodgkin lymphoma, stage III.
Selinexor
Selinexor is FDA approved